|
rs10146204
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For SNPs rs8021944, rs1256061 and rs10146204, ERβ expression was higher according to the rank sum test in lung tumors from patients with at least one minor allele.
|
23619141 |
2013 |
|
rs199976573
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, Klf5 is not required for lung tumor formation in an inducible oncogenic K-Ras(G12D) mouse model of lung tumorigenesis, and non-small cell lung cancer patients expressing high levels of KLF5 (21/258) have a significantly better disease-specific survival than those with intermediate to no KLF5 expression.
|
20639455 |
2010 |
|
rs1057519783
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The autopsied lung tumors harbored ALK G1202R (c. 3604 G>A) and the right renal metastasis harbored ALK G1202R (c. 3604 G>C); the mutation thus comprised different codon changes.
|
31374369 |
2019 |
|
rs113488022
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
|
rs113488022
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We combined (L597V)Braf with (G12D)Kras and found that (L597V)Braf modified (G12D)Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity (V600E)Braf mutant.
|
22892241 |
2012 |
|
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
|
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We combined (L597V)Braf with (G12D)Kras and found that (L597V)Braf modified (G12D)Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity (V600E)Braf mutant.
|
22892241 |
2012 |
|
rs121913369
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We combined (L597V)Braf with (G12D)Kras and found that (L597V)Braf modified (G12D)Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity (V600E)Braf mutant.
|
22892241 |
2012 |
|
rs1174029586
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutant Ki-ras(G12C) expression was sufficient for initial lung tumor transformation, required for maintenance of tumor phenotype, and induced transformation of lung epithelial cells by the activation of multiple effector pathways.
|
16051643 |
2005 |
|
rs947996134
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutant Ki-ras(G12C) expression was sufficient for initial lung tumor transformation, required for maintenance of tumor phenotype, and induced transformation of lung epithelial cells by the activation of multiple effector pathways.
|
16051643 |
2005 |
|
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo.
|
24213573 |
2014 |
|
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumor burden compared with activation of BRAF(V600E) alone.
|
26028035 |
2016 |
|
rs3743073
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that four of the variants (rs3829787, rs3841324, rs588765 and rs3743073) were associated with differential levels of genetic alterations measured as the levels of hydrophobic DNA adducts in the adjacent histologically normal tissue of the lung cancer patients and as TP53 mutations in their lung tumors.
|
23011884 |
2013 |
|
rs588765
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that four of the variants (rs3829787, rs3841324, rs588765 and rs3743073) were associated with differential levels of genetic alterations measured as the levels of hydrophobic DNA adducts in the adjacent histologically normal tissue of the lung cancer patients and as TP53 mutations in their lung tumors.
|
23011884 |
2013 |
|
rs775514340
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, a more rigorous test of the requirement for Notch signaling in lung oncogenesis, crossing the LSL-KRAS(G12D) mouse model with a transgenic with a similarly inducible global dominant-negative suppressor of Notch activity, LSL-DNMAML (dominant-negative mastermind-like), reveals no evidence of Notch pathway requirement for lung tumor initiation or growth in vivo.
|
21994468 |
2011 |
|
rs1242640031
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutant Ki-ras(G12C) expression was sufficient for initial lung tumor transformation, required for maintenance of tumor phenotype, and induced transformation of lung epithelial cells by the activation of multiple effector pathways.
|
16051643 |
2005 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors.
|
25596284 |
2015 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.
|
31689114 |
2019 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Similarly, deficiency of Puma impeded the regression of EGFR(L858R)-driven mouse lung tumors upon inactivation of the EGFR-activating mutant.
|
23532334 |
2013 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using specific and sensitive IHC assays, we analyzed the expression of anaplastic lymphoma kinase (ALK), EGFR L858R, and EGFR E746-A750del mutations in a subset of lung tumors, including those expressing ROS1.
|
22661537 |
2012 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Similarly, deficiency of Puma impeded the regression of EGFR(L858R)-driven mouse lung tumors upon inactivation of the EGFR-activating mutant.
|
23532334 |
2013 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using specific and sensitive IHC assays, we analyzed the expression of anaplastic lymphoma kinase (ALK), EGFR L858R, and EGFR E746-A750del mutations in a subset of lung tumors, including those expressing ROS1.
|
22661537 |
2012 |